Sep 28 close
This week Elanco's CEO Jeff Simmons outlined a growth and deleveraging strategy at the Bank of America Healthcare Conference, pointing to Quattro and Zenrelia as growth drivers, with targets of mid-single-digit revenue growth, high-single-digit EBITDA growth, and leverage falling to three times by year-end. Alongside the conference appearance, several executives, including the CEO, CFO, and an EVP, added deferred stock units to their holdings in mid-September.
Shares closed at $22.45, down slightly against a 50-day average of $23.99 and a 200-day average of $23.79, with the stock off 8.3% over one month and 9.3% over three months, though still up 18.7% over the past year. The GekkoIndex reads 67.2, placing the stock in the Accumulation zone, while the price sits 3.5% below the Gekko Fair Value of $23.27.
The next earnings report is set for 6 November, 38 days out and beyond a typical 20-trading-day holding window; the prior quarter beat estimates with $0.34 in adjusted EPS against a $0.27 estimate, though shares reacted -5.5% afterward. Over the last 90 days there have been 5 insider purchases totaling $1,473,069. Seasonally, the next 20 trading days have averaged a -3% return over 5 years, with gains in 3 of those years, a pattern worth noting alongside the current gap to fair value.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Elanco Animal Health scores 3 supportive, 3 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive3 mixed0 headwinds
Averages disagree
Close $22.45 sits between the 50-day ($23.99) and 200-day ($23.79) averages, or the averages disagree.
See the chart67.2, Accumulation
Reading 67.2 is in the Accumulation zone.
See the GekkoIndex3.5% below
Price is within 5% of Gekko Fair Value (3.5% below).
See fair valueLeans bullish
Last 90 days: 5 open-market insider purchases.
See smart moneyReports in 38 days
Next report Nov 6, 2026, 38 days away — outside a typical 20-trading-day hold.
See earnings−3.0% on average
From this point in the calendar, the next 20 trading days averaged −3% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Elanco Animal Health closed at $22.45 on Sep 28, 2026, +18.7% over the past year, inside a 52-week range of $18.93 to $27.98.
Use the left and right arrow keys to read daily values.
Put ELAN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Elanco Animal Health develops, manufactures, and sells products aimed at keeping pets and farm animals healthy. For dogs and cats, its lineup covers preventive treatments against parasites like fleas, ticks, and worms, sold under names such as Seresto, Advantage, Advantix, and Advocate, alongside medicines for pain, joint disease, ear infections, heart problems, and skin conditions marketed as Galliprant and Claro.
On the livestock side, Elanco makes vaccines, antibiotics, and parasiticides for poultry and aquaculture operations, plus nutritional additives like enzymes, probiotics, and prebiotics meant to support growth and overall health. For cattle, dairy herds, and pigs, it offers vaccines, antibiotics, implants, and parasiticides, including well-known products like Rumensin and Baytril. These goods reach the market through independent distributors, veterinary practices, and a wide range of animal producers spanning dairy and cattle farms to poultry, swine, and aquaculture businesses.
The company was founded in 1954 and is headquartered in Greenfield, Indiana. Its shares trade on the NYSE under the ticker ELAN.
Elanco Animal Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 67.2, in the Accumulation zone, down 2.7 points over five sessions.
Down 2.7 points over five sessions.
Reading for Sep 28, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 41 | −0.6% | +9.9% | ||
| Accumulation (current zone) | 205 | +1.6% | +4.3% | ||
| Neutral | 386 | +0.1% | 0.0% | ||
| Distribution | 39 | +0.7% | +4.5% | ||
| Selling | 1 | Too few readings yet | |||
Average ELAN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Elanco Animal Health trades 3.5% below Gekko Fair Value of $23.27, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Elanco Animal Health shares are worth, recalculated every trading day.
$23.27
Gekko Fair Value, Sep 29, 2026
3.5% below fair value · About fair value
Insiders filed 5 open-market purchases in Elanco Animal Health worth $1.47M, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
$1.47Min 5 open-market purchases
| Filed | Insider | Type | Value |
|---|---|---|---|
| Aug 21 | Kurzius Lawrence Erik director | Purchase | $936K |
| Aug 18 | Shiv O'Neill GC AND CORP SEC | Purchase | $94K |
| Aug 13 | Harrington Michael J director | Purchase | $109K |
| Aug 10 | Robert M Vanhimbergen EVP and CFO | Purchase | $97K |
| Aug 10 | Paul Herendeen Director | Purchase | $237K |
From Form 4 filings, dated to when each was filed.
No trades in ELAN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Elanco Animal Health has been buying back its own shares.
From company filings.
1of the funds Gekko tracks holds ELAN.
Elanco Animal Health reports on Nov 6, 2026, before the open (38 days away), and beat the EPS estimate in 7 of its last 8 reports.
Nov 6, 2026
Expected before the open, 38 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $0.34 est $0.27 | $1.37B est $1.31B | −5.5% |
| May 6, 2026 | $0.40 est $0.34 | $1.37B est $1.28B | +4.4% |
| Feb 24, 2026 | $0.13 est $0.11 | $1.14B est $1.09B | +8.4% |
| Nov 5, 2025 | $0.19 est $0.13 | $1.14B est $1.09B | −4.4% |
| Aug 7, 2025 | $0.26 est $0.20 | $1.24B est $1.09B | +19.2% |
| May 7, 2025 | $0.37 est $0.30 | $1.19B est $1.18B | +29.1% |
| Feb 25, 2025 | $0.14 est $0.15 | $1.02B est $1.21B | +0.2% |
| Nov 7, 2024 | $0.13 est $0.12 | $1.03B est $1.01B | +9.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Elanco Animal Health is $31.00, +38.1% from the last close, from 11 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 11 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 18 | Stifel Nicolaus | — | — |
| Aug 25 | TD Cowen | $32 | +42.5% |
| Aug 24 | TD Cowen | $32 | +42.5% |
| Aug 21 | Barclays | $30 | +33.6% |
| Aug 12 | Bank of America Securities | $34 | +51.4% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Sep 29, Elanco Animal Health averaged −3.0% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.2% | 3 of 5 |
| Next 10 trading days | −4.5% | 2 of 5 |
| Next 15 trading days | −3.8% | 2 of 5 |
| Next 20 trading days | −3.0% | 3 of 5 |
| Next 30 trading days | +1.1% | 2 of 5 |
For scale, ELAN’s typical 20-trading-day move in either direction is about 7.4%.
Elanco Animal Health’s market cap is $11.21B and revenue of $5.02B over the last twelve months.
Coverage of Elanco Animal Health this week reads neutral: 0 positive, 5 neutral and 0 negative headlines.
Elanco Animal Health’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| UTHRUnited Therapeutics | Accumulation | 23.6% below |
A peer links to its own page where one exists.
Elanco Animal Health’s market cap is $11.21B at the Sep 28, 2026 close of $22.45, with 499.5M shares outstanding.
The consensus analyst 12-month price target for Elanco Animal Health is $31.00, +38.1% from the last close. Of the 11 firms that rated the stock in the last 90 days, 10 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Elanco Animal Health is about fair value: the Sep 28, 2026 close of $22.45 is 3.5% below Gekko Fair Value of $23.27. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Elanco Animal Health is expected to report on Nov 6, 2026, before the market opens (38 days away). Analysts expect earnings of $0.20 per share on revenue of $1.21B. Elanco Animal Health beat the earnings estimate in 7 of its last 8 reports, moving 10.1% on average across the report.
Elanco Animal Health’s 52-week high is $27.98 and its 52-week low is $18.93; it closed at $22.45 on Sep 28, 2026, +18.7% over the past year. Over the last five years the shares peaked at $35.00 on Nov 5, 2021.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (gekkoindex, smart money and earnings risk), 3 as mixed (trend, fair value and seasonality). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.